4DMT to Participate in Upcoming Investor Conferences and Ophthalmology Innovation Summit XIV
November 14, 2024 08:00 ET
|
4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full...
4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones
November 13, 2024 16:05 ET
|
4D Molecular Therapeutics, Inc.
Presented positive interim data for 4D-150 in wet age-related macular degeneration (wet AMD) from PRISM Phase 1/2 clinical trial highlighting robust and durable clinical activity across diverse...
4DMT Announces Presentation at the 2024 North American Cystic Fibrosis Conference
September 23, 2024 08:00 ET
|
4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., Sept. 23, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full...
4DMT Highlights Robust and Durable Clinical Activity for 4D-150 and Design of 4FRONT Phase 3 Program at 4D-150 Wet AMD Development Day
September 18, 2024 16:05 ET
|
4D Molecular Therapeutics, Inc.
4D-150 demonstrated robust and durable clinical activity across all wet age-related macular degeneration (wet AMD) patient populations based on longest available follow-up data In broad population...
4DMT Announces Presentations at Upcoming Retina Conferences
September 05, 2024 08:00 ET
|
4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full...
4DMT to Participate in the 2024 Cantor Global Healthcare Conference
September 03, 2024 08:00 ET
|
4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full...
4DMT to Host 4D-150 Wet AMD Development Day on September 18, 2024
August 27, 2024 08:00 ET
|
4D Molecular Therapeutics, Inc.
Company to highlight 4D-150 product development strategy and Phase 1/2 PRISM clinical trial data in wet age-related macular degeneration (wet AMD), including longest available interim follow-up data ...
4DMT to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
August 12, 2024 08:00 ET
|
4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., Aug. 12, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full...
4DMT Reports Second Quarter 2024 Financial Results and Operational Highlights
August 08, 2024 16:05 ET
|
4D Molecular Therapeutics, Inc.
Announced positive interim results from the Population Extension cohort of the Phase 2 PRISM clinical trial for 4D-150 in a broad wet age-related macular degeneration (wet AMD) population, which...
4DMT Advances Leadership in Large Market Ophthalmology with Senior Management Hires and Formation of Ophthalmology Advisory Board
August 05, 2024 08:00 ET
|
4D Molecular Therapeutics, Inc.
Dhaval Desai, PharmD, named as Chief Development Officer; will oversee late-stage Product Development, Medical Affairs, Scientific Communications, Regulatory and Quality operations; most recently SVP...